Episodes

  • Key Messages from the ACC Board of Trustees Health Equity Action Plan

    Key Messages from the ACC Board of Trustees Health Equity Action Plan
    Nov 19 2024

    Disparities in health care disproportionally impact under-resourced and minority communities resulting in excess mortality and morbidity. Decreasing and eliminating these disparities will improve health statistics for all. The American College of Cardiology's (ACC) Health Equity Task Force is demonstrating its commitment to health equity through championing the improvement of patients’ lived experiences, population health, and clinician well-being while reducing health care costs—the Quadruple Aim of Health Equity.

    In this interview, Drs. Richard Chazal and Paul Douglass discuss Achieving Equitable Cardiovascular Care for All: ACC Board of Trustees Health Equity Task Force Action Plan. 

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Show more Show less
    11 mins
  • How Has Antithrombotic Therapy for PAD Changed Over the Last Decade?

    How Has Antithrombotic Therapy for PAD Changed Over the Last Decade?
    Nov 12 2024

    Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack, stroke, bleeding risk, and leg disease, which could lead to acute limb ischemia and amputation. Blood thinning medications (antithrombotic therapy) have shown rapid evolution and broad benefits and novel approved strategies that improve outcomes are available. It is imperative that clinicians select appropriate patients for use and consider the complex situations for management.

    In this interview, Drs. Cindy Grines and Marc Bonaca discuss Antithrombotic Strategies for Patients with Peripheral Artery Disease: JACC Scientific Statement.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Show more Show less
    11 mins
  • What Aspects of Cardiovascular Care are Most Primed for Disruption with AI?

    What Aspects of Cardiovascular Care are Most Primed for Disruption with AI?
    Nov 5 2024

    Patients can benefit from better healthcare access and outcomes by services that are enabled by artificial intelligence (AI). The current state of technology is evolving to now allow diagnosis of advanced conditions from simple diagnostic testing, broadening the scope of early diagnosis and treatment.

    What are the safe cards for the deployment of AI in real-world clinical care? In this interview, Drs. DJ Lakkireddy and Rohan Khera discuss Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Show more Show less
    14 mins
  • Real-time AI to Influence Clinical Decisions and Practice Towards Evidence-based Care: RAPIDxAI Trial

    Real-time AI to Influence Clinical Decisions and Practice Towards Evidence-based Care: RAPIDxAI Trial
    Oct 29 2024

    Can algorithms improve the management of patients with myocardial injury? Is there a tool to aid diagnosing patients faster and more accurately leading to appropriate treatment sooner to optimize results? This study highlights the challenges and opportunities associated with the integration of artificial intelligence (AI) into health care to improve outcomes.

    In this interview, Drs. Allen Taylor and Derek Chew discuss the findings of the RAPIDxAI trial: re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting evidence to practice using AI.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Show more Show less
    11 mins
  • Effect of Antihypertensive Timing on Mortality and Morbidity: BedMed and BedMed-Frail Trials

    Effect of Antihypertensive Timing on Mortality and Morbidity: BedMed and BedMed-Frail Trials
    Oct 22 2024
    The BedMed and BedMed-Frail trials assisted in providing clarity as to the daily timing of prescribed blood pressure medication. The two trials, one conducted in a general primary-care population and the other among nursing-home residents, determined no difference in major cardiovascular events or safety between blood pressure (BP) medication distribution in the evening or morning. In this interview, Drs. Anthony DeMaria and Scott Garrison review the BedMed and BedMed-Frail trials findings which proved the emphasis to patients is taking BP medication when they are least likely to forget, irrelevant of time of day. References: Pigazzani F, Dyar KA, Morant SV, et al. Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) study. EClinicalMedicine 2024;72:102633. Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 2022;400:1417-25. Hermida RC, Crespo JJ, Dominguez-Sardina M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2020;41:4565-76. Hermida RC, Ayala DE, Fernandez JR, et al. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 2013;30:280-314. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
    Show more Show less
    12 mins
  • Effect of Antihypertensive Timing on Mortality and Morbidity: BedMed and BedMed-Frail Trials

    Effect of Antihypertensive Timing on Mortality and Morbidity: BedMed and BedMed-Frail Trials
    Oct 22 2024
    The BedMed and BedMed-Frail trials assisted in providing clarity as to the daily timing of prescribed blood pressure medication. The two trials, one conducted in a general primary-care population and the other among nursing-home residents, determined no difference in major cardiovascular events or safety between blood pressure (BP) medication distribution in the evening or morning. In this interview, Drs. Anthony DeMaria and Scott Garrison review the BedMed and BedMed-Frail trials findings which proved the emphasis to patients is taking BP medication when they are least likely to forget, irrelevant of time of day. References: Pigazzani F, Dyar KA, Morant SV, et al. Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) study. EClinicalMedicine 2024;72:102633. Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 2022;400:1417-25. Hermida RC, Crespo JJ, Dominguez-Sardina M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2020;41:4565-76. Hermida RC, Ayala DE, Fernandez JR, et al. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 2013;30:280-314. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
    Show more Show less
    12 mins
  • Potassium Supplementation and the Prevention of Afib After Cardiac Surgery: TiGHT-K Trial

    Potassium Supplementation and the Prevention of Afib After Cardiac Surgery: TiGHT-K Trial
    Oct 15 2024
    The goal of the TIGHT K trial was to evaluate if prescribing relaxed control of potassium levels and only giving supplements in the rare event that levels became pathologically low was equally as effective in preventing atrial fibrillation (AFib) after cardiac surgery as tightly controlling levels. In this interview, Drs. Steven Nissen and Benjamin O’Brien discuss the TIGHT K trial results which proved that practitioners can safely cease the widespread practice of maintaining high-normal potassium levels after isolated coronary artery bypass grafting surgery. Additional benefits include improved tpatient experience and reduced patient cost. References: O’Brien B, Campbell NG, Allen E, et al; TIGHT K Investigators. Potassium supplementation and prevention of atrial fibrillation after cardiac surgery: the TIGHT K randomized clinical trial. JAMA 2024;332:979-88. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
    Show more Show less
    9 mins
  • Older Patients With NSTEMI Randomized Interventional Treatment: SENIOR-RITA Trial

    Older Patients With NSTEMI Randomized Interventional Treatment: SENIOR-RITA Trial
    Oct 8 2024
    The goal of the SENIOR RITA trial was to evaluate routine invasive therapy compared with conservative therapy among older patients with non–ST-elevation myocardial infarction. Additionally, the trial assessed whether optimal medical therapy or coronary angiography and stents are beneficial in older adults with heart attacks. In this interview, Drs. Nanette Kass Wenger and Vijay Kunadian discuss the SENIOR RITA trial results and the importance of individualizing routine invasive therapy in individuals ≥75 years of age. References: Kunadian V, Mossop H, Shields C, et al., for the British Heart Foundation SENIOR-RITA Trial Team and Investigators. Invasive Treatment Strategy for Older Patients With Myocardial Infarction. N Engl J Med 2024;Sep 1:[Epub ahead of print]. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
    Show more Show less
    7 mins